Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain

Oncogene volume 22, pages 2011–2020 (2003)Cite this article

Abstract

B-Myb is a widely expressed member of the myb oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the α2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the α2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of α2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein–protein interactions. B-Myb mutants with either deletion of aa 374–581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated α2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Arsura M, Luchetti MM, Erba E, Golay J, Rambaldi A and Introna M . (1994). Blood, 83, 1778–1790.

  • Bartsch O, Horstmann S, Toprak K, Klempnauer KH and Ferrari S . (1999). Eur. J. Biochem., 260, 384–391.

  • Beldekas JC, Gerstenfeld L, Sonenshein GE and Franzblau C . (1982). J. Biol. Chem., 257, 12252–12256.

  • Bessa M, Saville MK and Watson RJ . (2001). Oncogene, 20, 3376–3386.

  • Bruno MD, Whitsett JA, Ross GF and Korfhagen TR . (1999). J. Biol. Chem., 274, 27523–27528.

  • Cervellera MN, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B and Sala A . (2000). J. Biol. Chem., 275, 21055–21060.

  • Cervellera MN and Sala A . (2000). J. Biol. Chem., 275, 10692–10696.

  • Charrasse S, Carena I, Brondani V, Klempnauer KH and Ferrari S . (2000). Oncogene, 19, 2986–2995.

  • Foos G, Grimm S and Klempnauer KH . (1992). EMBO J., 11, 4619–4629.

  • Golay J, Capucci A, Arsura M, Castellano M, Rizzo V and Introna M . (1991). Blood, 77, 149–158.

  • Grassilli E, Salomoni P, Perrotti D, Franceschi C and Calabretta B . (1999). Cancer Res., 59, 2451–2456.

  • Horstmann S, Ferrari S and Klempnauer KH . (2000). Oncogene, 19, 298–306.

  • Howe KM and Watson RJ . (1991). Nucleic Acids Res., 19, 3913–3919.

  • Iwai N, Kitajima K, Sakai K, Kimura T and Nakano T . (2001). Oncogene, 20, 1425–1434.

  • Johnson LR, Johnson TK, Desler M, Luster TA, Nowling T, Lewis RE and Rizzino A . (2002). J. Biol. Chem., 277, 4088–4097.

  • Johnson TK, Schweppe RE, Septer J and Lewis RE . (1999). J. Biol. Chem., 274, 36741–36749.

  • Kypreos KE, Marhamati DJ and Sonenshein GE . (1999). Matrix Biol., 18, 275–285.

  • Kypreos KE, Nugent MA and Sonenshein GE . (1998). Cell Growth Differ., 9, 723–730.

  • Lam EW, Robinson C and Watson RJ . (1992). Oncogene, 7, 1885–1890.

  • Lane S, Farlie P and Watson R . (1997). Oncogene, 14, 2445–2453.

  • Li X and McDonnell DP . (2002). Mol. Cell Biol., 22, 3663–3673.

  • Marhamati DJ and Sonenshein GE . (1996). J. Biol. Chem., 271, 3359–3365.

  • Masselink H, Vastenhouw N and Bernards R . (2001). Cancer Lett., 171, 87–101.

  • Mizuguchi G, Kanei-Ishii C, Takahashi T, Yasukawa T, Nagase T, Horikoshi M, Yamamoto T and Ishii S . (1995). J. Biol. Chem., 270, 9384–9389.

  • Mizuguchi G, Nakagoshi H, Nagase T, Nomura N, Date T, Ueno Y and Ishii S . (1990). J. Biol. Chem., 265, 9280–9284.

  • Muller-Tidow C, Wang W, Idos GE, Diederichs S, Yang R, Readhead C, Berdel WE, Serve H, Saville M, Watson R and Koeffler HP . (2001). Blood, 97, 2091–2097.

  • Nakagoshi H, Takemoto Y and Ishii S . (1993). J. Biol. Chem., 268, 14161–14167.

  • Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S and Ishizaki R . (1988). Nucleic Acids Res., 16, 11075–11089.

  • Oh IH and Reddy EP . (1998). Mol. Cell Biol., 18, 499–511.

  • Oh IH and Reddy EP . (1999). Oncogene, 18, 3017–3033.

  • Penkov D, Tanaka S, Di Rocco G, Berthelsen J, Blasi F and Ramirez F . (2000). J. Biol. Chem., 275, 16681–16689.

  • Piccinini G, Golay J, Flora A, Songia S, Luchetti M, Gabrielli A and Introna M . (1999). J. Invest. Dermatol., 112, 191–196.

  • Sala A, Kundu M, Casella I, Engelhard A, Calabretta B, Grasso L, Paggi MG, Giordano A, Watson RJ, Khalili K and Peschle C . (1997). Proc. Natl. Acad. Sci. USA, 94, 532–536.

  • Sala A and Watson R . (1999). J. Cell Physiol., 179, 245–250.

  • Takemoto Y, Tashiro S, Handa H and Ishii S . (1994). FEBS Lett., 350, 55–60.

  • Tanaka Y, Patestos NP, Maekawa T and Ishii S . (1999). J. Biol. Chem., 274, 28067–28070.

  • Tashiro S, Takemoto Y, Handa H and Ishii S . (1995). Oncogene, 10, 1699–1707.

  • Ying GG, Proost P, van Damme J, Bruschi M, Introna M and Golay J . (2000). J. Biol. Chem., 275, 4152–4158.

  • Ziebold U, Bartsch O, Marais R, Ferrari S and Klempnauer KH . (1997). Curr. Biol., 7, 253–260.

Download references

Acknowledgements

We thank R Watson, F Ramirez, S Ishii, and J Xiao for generously providing cloned DNAs. Muriel Jeay is acknowledged for assistance in preparation of the manuscript and K Symes for use of the Axiovert 35 microscope. This work was supported by grants from the Association pour la Recherche sur le Cancer (SJ), Philippe Foundation (SJ) and the NIH 5 P01 HL13262 (GES).

Author information

Authors and Affiliations

  1. Department of Biochemistry, Boston University Medical School, 715 Albany Street, Boston, 02118-2394, MA, USA

    Constantinos Petrovas, Sébastien Jeay & Gail E Sonenshein

  2. Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, 68198-6805, NE, USA

    Robert E Lewis

Authors
  1. Constantinos Petrovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sébastien Jeay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gail E Sonenshein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gail E Sonenshein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrovas, C., Jeay, S., Lewis, R. et al. B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain. Oncogene 22, 2011–2020 (2003). https://doi.org/10.1038/sj.onc.1206231

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206231

Keywords

This article is cited by

Search

Advanced search

Quick links